Efficacy and Safety of Sotalol in Children With Arrhythmia
- Registration Number
- NCT03895411
- Lead Sponsor
- Shengjing Hospital
- Brief Summary
This study aims to investigate the efficacy and safety of oral sotalol alone or combination with other anti-arrhythmic medicines in the treatment of arrhythmias in children. The study will regularly monitor the Holter, electrocardiogram (ECG), Echocardiography (Echo), blood routine, urine routine, serum ion, liver and kidney function, troponin I, hypersensitive troponin T, N-terminal pro-brain natriuretic peptide (NT pro-BNP), etc, before and after receive sotalol therapy. Compare the degree of arrhythmia improvement in patients and the side effects after oral sotalol.
- Detailed Description
Monitoring the Holter, ECG, Echocardiography , blood routine, urine routine, serum ion, liver and kidney function, troponin I, hypersensitive troponin T, NT pro-BNP beforehand. Eligible patients should stop all anti-arrhythmia drugs and digitalis, tricyclic antidepressants, beta blockers or calcium antagonists for at least 5 half-lives, and then do Holter. Randomly grouped. Judging the results according to the situation before and after oral sotalol.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
- Age 0 day to 14 year-old
- Diagnosis of tachycardia (paroxysmal supraventricular tachycardia, paroxysmal atrial tachycardia, ventricular tachycardia, idiopathic ventricular tachycardia, premature ventricular contraction) and had an episode within 3 months; Premature Ventricular Contractions (PVC) (total 10000 times/d, or>5000 times/d with multiple source PVC, or total > 3000 times/d but with paired PVC+ multiple source PVC, or ventricular tachycardia);
- Although PVC≤ 10000 times/d, but there are obvious symptoms such as palpitation, chest tightness, fatigue, dizziness and other symptoms that need improvement.
- Signed informed consent before the trial
- Good compliance
- Heart failure that is ineffective in conventional treatment;
- Left ventricular ejection fraction (LVEF) ≤ 50%;
- Suffering from bronchial asthma;
- Resting sinus heart rate (HR) in newborns <90 bpm; -8 yrs <80 bpm; ≥ 8 yrs <60 bpm;
- Corrected QT Interval (QTc) ≥ 450ms;
- II ° -III ° atrioventricular block (AVB);
- Severe liver, renal dysfunction, acute myocardial infarction, acute myocarditis, electrolyte imbalance have not been corrected;
- The child has undergone major surgery in the past 4 weeks;
- The child has participated in other clinical trials in the past 4 weeks;
- The child has digestive, nervous, circulatory, kidney or liver disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Propafenone Propafenone Oral Propafenone 5mg/kg/time, pre 8h Combination therapy: betaloc Sotalol betaloc Oral sotalol 2.5mg/kg/time, per 12h. Combination therapy: betaloc Sotalol sotalol Oral sotalol 2.5mg/kg/time, per 12h. Combination therapy: betaloc Propafenone betaloc Oral Propafenone 5mg/kg/time, pre 8h Combination therapy: betaloc
- Primary Outcome Measures
Name Time Method QT interval of ECG 3 month
- Secondary Outcome Measures
Name Time Method Blood pressure 1 week, 3 month Wed Blood Cell (WBC) 1 week, 3 month The indicator is obtained through blood routine.
Platelet 1 week, 3 month The indicator is obtained through blood routine.
Aspertate aminotransferase (AST) 1 week, 3 month The indicator is obtained through liver function test.
Hemoglobin 1 week, 3 month The indicator is obtained through blood routine.
Creatinine 1 week, 3 month The indicator is obtained through kidney function test.
Red Blood Cell (RBC) 1 week, 3 month The indicator is obtained through blood routine.
Albumin 1 week, 3 month The indicator is obtained through liver function test.
Alanine aminotransferase (ALT) 1 week, 3 month The indicator is obtained through liver function test.
Trial Locations
- Locations (1)
Shenjing Hospital
🇨🇳Shenyang, Liaoning, China